The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, NA-1, in reducing global disability in subjects with major acute ischemic stroke (AIS) with a small established infarct core and with good collateral circulation who are selected for endovascular revascularization.
Contact site for start date.
Please contact ClinicalResearch@sutterhealth.org about Study ESCAPE-NA-1
View study details on ClinicalTrials.gov
18 years and older
June 01, 2018